Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin TM (RX-5902)
December 11 2013 - 7:00AM
Business Wire
Further expands IP covering Supinoxin,
following the Company’s receipt of composition of matter patent
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage
biopharmaceutical company developing potential best-in-class
oncology therapies, today announced that it has been issued United
States Patent, No. 8,598,173, which covers a method for treating
solid cancer tumors including ovarian, breast, prostate, liver,
lung, kidney, colon, pancreatic and stomach for its clinical
development candidate SupinoxinTM (RX-5902). Rexahn had
previously received a composition of matter patent from the United
Stated Patent and Trademark Office covering the structure of
Supinoxin.
“We are progressing on schedule with our Phase I dose-escalation
clinical trial for Supinoxin in cancer patients with solid cancer
tumors. Having initiated patient enrollment in August, we expect
data in the first half of 2014, which will help inform the study
design for future Phase II trials on Supinoxin,” stated Rexahn CEO
Peter D. Suzdak, Ph.D.
“We are committed to developing cancer treatments that
specifically target cancer cells, excluding healthy tissue, so that
cancer can be treated with increased efficacy and reduced toxicity.
Strengthening our IP portfolio as we advance in our clinical trials
adds critical value to our company,” added Dr. Suzdak.
In-vitro studies have shown that Supinoxin reduces the spread of
18 different human cancer cells lines. Supinoxin has also shown
that it can eliminate cancer cells which were resistant to other
widely used cancer drugs including docetaxel, cisplatin and
gemcitabine. Supinoxin is an orally available new chemical entity
exhibiting potent antitumor properties in several types of tumors
and has also show strong anti-proliferative activity against known
anti-cancer drug-resistant cancer cells, and a synergistic effect
with known anti-cancer drugs as well.
About SupinoxinTM (RX-5902)
Supinoxin is an orally administered, first-in-class, small
molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68).
P-p68, which is selectively expressed in cancer cells but absent in
normal tissue, increases the activity of multiple cancer related
genes including cyclin D1, c-jun and c-myc, and plays a role in
tumor progression and metastasis. Over-expression of P-p68 has been
observed in solid tumors such as melanoma, colon, ovarian and
lung.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical
company dedicated to developing best-in-class therapeutics for the
treatment of cancer. Rexahn currently has three clinical stage
oncology candidates, Archexin®, RX-3117, and SupinoxinTM
(RX-5902), and a robust pipeline of preclinical compounds to treat
multiple types of cancer. Rexahn has also developed proprietary
drug discovery platform technologies in the areas of
Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines,
3D-GOLD, and TIMES. For more information, please visit
www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal
with information that is not historical, these are forward-looking
statements under the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about Rexahn’s plans, objectives, expectations and intentions with
respect to future operations and products and other statements
identified by words such as “will,” “potential,” “could,” “can,”
“believe,” “intends,” “continue,” “plans,” “expects,”
“anticipates,” “estimates,” “may,” other words of similar meaning
or the use of future dates. Forward-looking statements by their
nature address matters that are, to different degrees, uncertain.
Uncertainties and risks may cause Rexahn’s actual results to be
materially different than those expressed in or implied by Rexahn’s
forward-looking statements. For Rexahn, particular uncertainties
and risks include, among others, the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals
and achieving market acceptance; the timing and success of clinical
testing; the timing of the conduct of clinical testing; the timing
of the receipt and disclosure of clinical data and Rexahn’s need
for and ability to obtain additional financing. More detailed
information on these and additional factors that could affect
Rexahn’s actual results are described in Rexahn’s filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and subsequent quarterly reports on Form
10-Q. All forward-looking statements in this news release speak
only as of the date of this news release. Rexahn undertakes no
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
The Trout Group LLCTricia Truehart,
646-378-2953ttruehart@troutgroup.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Jul 2023 to Jul 2024